Baseline characteristics ‘
In 7 studies involving a total of 39,995 participants who met the inclusion criteria, 20,368 (50.9%) received Finerenone and 19,627 (49%) received a placebo. Except for Bakris 2015[13] Katayama 2017 [17], which were in phase 2, all included trials were in phase 3. Table 1 and 2 provides information about baseline characteristics, and supplementary tables 3 and 4 provide information about comorbidities, and previous medication history.